231 related articles for article (PubMed ID: 22524618)
1. The combination of olaparib and camptothecin for effective radiosensitization.
Miura K; Sakata K; Someya M; Matsumoto Y; Matsumoto H; Takahashi A; Hareyama M
Radiat Oncol; 2012 Apr; 7():62. PubMed ID: 22524618
[TBL] [Abstract][Full Text] [Related]
2. PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53.
Liu Q; Gheorghiu L; Drumm M; Clayman R; Eidelman A; Wszolek MF; Olumi A; Feldman A; Wang M; Marcar L; Citrin DE; Wu CL; Benes CH; Efstathiou JA; Willers H
Oncogene; 2018 May; 37(21):2793-2805. PubMed ID: 29511347
[TBL] [Abstract][Full Text] [Related]
3. [Effect and Mechanism of Radiosensitization of Poly (ADP-Ribose) Polymerase Inhibitor n Lewis Cells and Xenografts].
Wang W; Duan B; Zeng L
Zhongguo Fei Ai Za Zhi; 2016 Jan; 19(1):16-23. PubMed ID: 26805733
[TBL] [Abstract][Full Text] [Related]
4. Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells.
Verhagen CV; de Haan R; Hageman F; Oostendorp TP; Carli AL; O'Connor MJ; Jonkers J; Verheij M; van den Brekel MW; Vens C
Radiother Oncol; 2015 Sep; 116(3):358-65. PubMed ID: 25981132
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.
Senra JM; Telfer BA; Cherry KE; McCrudden CM; Hirst DG; O'Connor MJ; Wedge SR; Stratford IJ
Mol Cancer Ther; 2011 Oct; 10(10):1949-58. PubMed ID: 21825006
[TBL] [Abstract][Full Text] [Related]
6. The use of Olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks.
Tahara M; Inoue T; Sato F; Miyakura Y; Horie H; Yasuda Y; Fujii H; Kotake K; Sugano K
Mol Cancer Ther; 2014 May; 13(5):1170-80. PubMed ID: 24577941
[TBL] [Abstract][Full Text] [Related]
7. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
[TBL] [Abstract][Full Text] [Related]
8. BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibiting homologous recombination repair.
Kong Y; Xu C; Sun X; Sun H; Zhao X; He N; Ji K; Wang Q; Du L; Wang J; Zhang M; Liu Y; Wang Y; Liu Q
Cancer Biol Med; 2021 Dec; 19(8):1150-71. PubMed ID: 34846107
[TBL] [Abstract][Full Text] [Related]
9. An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma.
Nile DL; Rae C; Hyndman IJ; Gaze MN; Mairs RJ
BMC Cancer; 2016 Aug; 16():621. PubMed ID: 27515310
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia Potentiates the Radiation-Sensitizing Effect of Olaparib in Human Non-Small Cell Lung Cancer Xenografts by Contextual Synthetic Lethality.
Jiang Y; Verbiest T; Devery AM; Bokobza SM; Weber AM; Leszczynska KB; Hammond EM; Ryan AJ
Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):772-81. PubMed ID: 27020103
[TBL] [Abstract][Full Text] [Related]
11. PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation.
Mao Y; Huang X; Shuang Z; Lin G; Wang J; Duan F; Chen J; Li S
Cancer Med; 2018 Apr; 7(4):1285-1296. PubMed ID: 29479816
[TBL] [Abstract][Full Text] [Related]
12. PARP inhibitor olaparib sensitizes esophageal carcinoma cells to fractionated proton irradiation.
Kageyama SI; Junyan D; Hojo H; Motegi A; Nakamura M; Tsuchihara K; Akimoto T
J Radiat Res; 2020 Mar; 61(2):177-186. PubMed ID: 31976528
[TBL] [Abstract][Full Text] [Related]
13. Poly (ADP-ribose) polymerase inhibitors sensitize cancer cells to hypofractionated radiotherapy through altered selection of DNA double-strand break repair pathways.
Seo Y; Tamari K; Takahashi Y; Minami K; Tatekawa S; Isohashi F; Suzuki O; Akino Y; Ogawa K
Int J Radiat Biol; 2022; 98(7):1222-1234. PubMed ID: 34919022
[TBL] [Abstract][Full Text] [Related]
14. Poly(ADP-ribose) polymerase inhibitors combined with external beam and radioimmunotherapy to treat aggressive lymphoma.
Schaefer NG; James E; Wahl RL
Nucl Med Commun; 2011 Nov; 32(11):1046-51. PubMed ID: 21956491
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of PARP1-dependent end-joining contributes to Olaparib-mediated radiosensitization in tumor cells.
Kötter A; Cornils K; Borgmann K; Dahm-Daphi J; Petersen C; Dikomey E; Mansour WY
Mol Oncol; 2014 Dec; 8(8):1616-25. PubMed ID: 25028150
[TBL] [Abstract][Full Text] [Related]
16. Olaparib enhances sensitization of BRCA-proficient breast cancer cells to x-rays and protons.
Park S; Choi C; Kim H; Shin YJ; Oh Y; Park W; Cho WK; Kim N
Breast Cancer Res Treat; 2024 Feb; 203(3):449-461. PubMed ID: 37902934
[TBL] [Abstract][Full Text] [Related]
17. PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors.
Parsels LA; Karnak D; Parsels JD; Zhang Q; Vélez-Padilla J; Reichert ZR; Wahl DR; Maybaum J; O'Connor MJ; Lawrence TS; Morgan MA
Mol Cancer Res; 2018 Feb; 16(2):222-232. PubMed ID: 29133592
[TBL] [Abstract][Full Text] [Related]
18. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.
Vance S; Liu E; Zhao L; Parsels JD; Parsels LA; Brown JL; Maybaum J; Lawrence TS; Morgan MA
Cell Cycle; 2011 Dec; 10(24):4321-9. PubMed ID: 22134241
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Parp1 by BMN673 Effectively Sensitizes Cells to Radiotherapy by Upsetting the Balance of Repair Pathways Processing DNA Double-Strand Breaks.
Soni A; Li F; Wang Y; Grabos M; Krieger LM; Chaudhary S; Hasan MSM; Ahmed M; Coleman CN; Teicher BA; Piekarz RL; Wang D; Iliakis GE
Mol Cancer Ther; 2018 Oct; 17(10):2206-2216. PubMed ID: 29970481
[TBL] [Abstract][Full Text] [Related]
20. Radiosensitization effect of poly(ADP-ribose) polymerase inhibition in cells exposed to low and high liner energy transfer radiation.
Hirai T; Shirai H; Fujimori H; Okayasu R; Sasai K; Masutani M
Cancer Sci; 2012 Jun; 103(6):1045-50. PubMed ID: 22404155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
